N/A
Completed N=54
Effect of Policosanol as Monotherapy and Adjunctive to Statin Therapy
High Cholesterol
Source: ClinicalTrials.gov NCT00510809 ↗
Enrolled (actual)
54
Serious AEs
0.0%
Results posted
Jul 2012
Primary outcomePrimary: Lipid Profile — -5; -5; 2; -4 mg/dl
Summary
To determine the effects of policosanol on the cholesterol profile.
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Lipid Profile |
-5; -5; 2; -4; 4; 0 | — |
| SECONDARY Adverse Events Reported |
6; 10; 5 | — |
Eligibility Criteria
Inclusion Criteria
- LDL > 100
- Male or Non-Pregnant Female. Women must be surgically sterile or postmenopausal and not using hormone replacement therapy (HRT) or using a stable, consistent HRT dose with intentions to continue therapy throughout the course of the study
- Mentally competent to understand study rationale and protocol
- Speak and read English
- Currently receiving low to moderate dose statin therapy with plans to continue to the same dose for at least 8 weeks. Low to moderate dose statins include the following daily doses: atorvastatin ≤20 mg, fluvastatin ≤40 mg, lovastatin ≤40 mg, pravastatin ≤40 mg, rosuvastatin ≤10 mg, simvastatin ≤ 40 mg
Exclusion Criteria
- LDL 500mg/day], bile-acid sequestrants, ezetimibe, fibrates and high-dose Omega-3 fish oils [>900mg of combined EPA/DHA daily])
- Currently taking medications which have the potential to interact with policosanol (i.e. warfarin, high-dose aspirin)
- Active liver disease or ALT level 2.5 times the upper limit of normal
- Chronic disease involving hepatic, renal or coronary artery disease
- Currently experiencing "flu-like" symptoms
- Currently experiencing any form of acute physical injury
- Acute psychiatric disorders
- Immuno-compromised state
- Currently taking systemic steroidal drugs
- Currently pregnant or lactating
- Females of childbearing potential
- Dependence on alcohol or illicit drugs
- Participation in any other clinical trial within the last 30 days
- Displays s/s of acute systemic infection (oral temperature >100°F, WBC>12x10³/µL)
Data sourced from ClinicalTrials.gov (NCT00510809). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.